retatrutide clinical trials review What Is And How Does It Work? Who Makes Retatrutide? Company Behind

Early data suggests greater weight reduction and improved glycemic control compared to GLP-1-only peptides

Do either of these have long-term outcome data

July 1, 2026 If your time is short Retatrutide is a weekly injection being studied as a treatment for obesity, type 2 diabetes, knee osteoarthritis pain, obstructive sleep apnea, chronic low back pain and liver disease

Vidal-Alaball J, Butler CC, Cannings-John R, et al

Unlike earlier GLP-1 receptor agonists like semaglutide (Ozempic/Wegovy) that target a single hormone pathway, or tirzepatide (Mounjaro/Zepbound) that targets two, retatrutide activates three distinct metabolic receptors : GIP, GLP-1, and glucagon

Reduction in Appetite and Caloric Intake: By affecting hunger hormones and gastric emptying, GLP-1 can help reduce appetite and caloric intake, leading to weight loss